Why I’d still buy the GSK share price after its 10% rise

G A Chester still sees good value in GlaxoSmithKline plc (LON:GSK) and in a smaller-cap sector peer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GlaxoSmithKline (LSE: GSK) share price has climbed 10% over the last three months against a flat FTSE 100. Meanwhile, smaller-cap Alliance Pharma (LSE: APH) has seen its shares decline 10% over the same period. In this article, I’ll discuss why I’d still buy GSK, despite the surge in its market valuation, and why I also rate out-of-favour Alliance a ‘buy’.

Business model

Alliance owns or licenses the rights to more than 90 consumer healthcare products and pharmaceuticals. With wide international reach through an extensive network of distributors, it generates sales in more than 100 countries.

Many of its products are sold in a limited number of local markets and require little or no promotional investment. Its promotional investment is focused on a small number of brands with significant international or multi-territory reach, including Kelo-cote (a scar treatment product) and Vamousse (a product for the prevention and treatment of head lice).

Valuation highly attractive

Alliance has a strong record of acquisitions and organic growth. A half-year trading update last month told us group revenue increased 28%, with organic growth of 10%. City analysts’ full-year forecasts are for revenue of £144m, an increase of £100m on the £44m it posted five years ago.

One of the biggest 50 companies on London’s junior AIM market, Alliance’s market capitalisation is £351m at a current share price of 67.6p. Therefore, the forward price-to-sales (P/S) ratio is 2.4. Meanwhile, a City consensus earnings per share (EPS) forecast of 5p (10% ahead of last year) gives a price-to-earnings (P/E) ratio of 13.5, while a forecast well-covered 1.6p dividend produces a prospective yield of 2.4%.

In a defensive sector, and with a low-risk business model and strong record of growth, I think Alliance’s valuation is highly attractive.

More highly rated stock

GlaxoSmithKline is not only a giant — its market capitalisation is £84.5bn at a share price of 1,693p — but also a more highly rated stock than Alliance on P/S and P/E. On forecast revenue of £32.4bn, its P/S is 2.6, and on forecast EPS of 115p (4% down on last year), its P/E is 14.7.

GSK’s dividend yield of 4.7%, on a forecast payout of 80p, is higher than Alliance’s but less well covered by EPS. Alliance’s yield would be 5.1%, if it paid out the same proportion of earnings as its FTSE 100 peer.

On the face of it, GSK may not seem to offer particularly good value. However, I believe there’s one big reason why it does.

Still good value

Earlier this month, GSK announced it had completed its planned transaction with Pfizer to combine their consumer healthcare businesses into a world-leading joint venture. GSK has a 68% controlling interest and Pfizer an interest of 32%. This is a step on the way to GSK demerging the joint venture from the company and listing the GSK Consumer Healthcare business on the UK stock market.

Chief executive Emma Walmsley said: “This is an important moment for the group, laying the foundation for two great companies, one in pharmaceuticals and vaccines, and one in consumer health.”

A number of analysts and institutional investors had long argued that breaking up the group would unlock value for shareholders. Neil Woodford once suggested a potential sum-of-the-parts valuation of £100bn. This compares with GSK’s current market value of £85bn, and is the principal reason why I still see good value in the stock today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Alliance Pharma. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »